Article

Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility

Science (Impact Factor: 31.48). 07/2014; 345(6193). DOI: 10.1126/science.1253533

ABSTRACT Circulating tumor cells (CTCs) are present at low concentrations in the peripheral blood of patients with solid tumors. It has been proposed that the isolation, ex vivo culture, and characterization of CTCs may provide an opportunity to noninvasively monitor the changing patterns of drug susceptibility in individual patients as their tumors acquire new mutations. In a proof-of-concept study, we established CTC cultures from six patients with estrogen receptor-positive breast cancer. Three of five CTC lines tested were tumorigenic in mice. Genome sequencing of the CTC lines revealed preexisting mutations in the PIK3CA gene and newly acquired mutations in the estrogen receptor gene (ESR1), PIK3CA gene, and fibroblast growth factor receptor gene (FGFR2), among others. Drug sensitivity testing of CTC lines with multiple mutations revealed potential new therapeutic targets. With optimization of CTC culture conditions, this strategy may help identify the best therapies for individual cancer patients over the course of their disease.

Download full-text

Full-text

Available from: Nicola Aceto, Jul 23, 2014
3 Followers
 · 
343 Views
  • Nature reviews. Cancer 07/2014; DOI:10.1038/nrc3799 · 37.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The type of collision between the European and the Adriatic plates in the easternmost Alps is one the most interesting questions regarding the Alpine evolution. Tectonic processes such as compression, escape and uplift are interconnected and shape this area. We can understand these ongoing processes better, if we look for signs of the deformation within the Earth's deep crust of the region. By collecting records from permanent and temporary seismic networks, we assemble a receiver function dataset, and analyze it with the aim of giving new insights on the structure of the lower crust and of the shallow portion of the upper mantle, which are inaccessible to direct observation. Imaging is accomplished by performing common conversion depth stacks along three profiles that crosscut the Eastern Alpine orogen, and allow isolating features consistently persistent in the area. The study shows a moderately flat Moho underlying a seismically anisotropic middle-lower crust from the Southern Alps to the Austroalpine nappes. The spatial progression of anisotropic axes reflects the orientation of the relative motion and of the stress field detected at the surface. These observations suggest that distributed deformation is due to the effect of the Alpine indentation. In the shallow upper mantle right below the Moho interface, a further anisotropic layer is recognized, extended from the Bohemian Massif to the Northern Calcareous Alps.
    Journal of Geodynamics 08/2014; http://www.sciencedirect.com/science/article/pii/S0264370714001033. DOI:10.1016/j.jog.2014.07.005 · 2.62 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Conspectus Circulating tumor cells (CTCs) are cancer cells that break away from either a primary tumor or a metastatic site and circulate in the peripheral blood as the cellular origin of metastasis. With their role as a "tumor liquid biopsy", CTCs provide convenient access to all disease sites, including that of the primary tumor and the site of fatal metastases. It is conceivable that detecting and analyzing CTCs will provide insightful information in assessing the disease status without the flaws and limitations encountered in performing conventional tumor biopsies. However, identifying CTCs in patient blood samples is technically challenging due to the extremely low abundance of CTCs among a large number of hematologic cells. To address this unmet need, there have been significant research endeavors, especially in the fields of chemistry, materials science, and bioengineering, devoted to developing CTC detection, isolation, and characterization technologies. Inspired by the nanoscale interactions observed in the tissue microenvironment, our research team at UCLA pioneered a unique concept of "NanoVelcro" cell-affinity substrates, in which CTC capture agent-coated nanostructured substrates were utilized to immobilize CTCs with high efficiency. The working mechanism of NanoVelcro cell-affinity substrates mimics that of Velcro: when the two fabric strips of a Velcro fastener are pressed together, tangling between the hairy surfaces on two strips leads to strong binding. Through continuous evolution, three generations (gens) of NanoVelcro CTC chips have been established to achieve different clinical utilities. The first-gen NanoVelcro chip, composed of a silicon nanowire substrate (SiNS) and an overlaid microfluidic chaotic mixer, was created for CTC enumeration. Side-by-side analytical validation studies using clinical blood samples suggested that the sensitivity of first-gen NanoVelcro chip outperforms that of FDA-approved CellSearch. In conjunction with the use of the laser microdissection (LMD) technique, second-gen NanoVelcro chips (i.e., NanoVelcro-LMD), based on polymer nanosubstrates, were developed for single-CTC isolation. The individually isolated CTCs can be subjected to single-CTC genotyping (e.g., Sanger sequencing and next-generation sequencing, NGS) to verify the CTC's role as tumor liquid biopsy. Created by grafting of thermoresponsive polymer brushes onto SiNS, third-gen NanoVelcro chips (i.e., Thermoresponsive NanoVelcro) have demonstrated the capture and release of CTCs at 37 and 4 °C, respectively. The temperature-dependent conformational changes of polymer brushes can effectively alter the accessibility of the capture agent on SiNS, allowing for rapid CTC purification with desired viability and molecular integrity. This Account summarizes the continuous evolution of NanoVelcro CTC assays from the emergence of the original idea all the way to their applications in cancer research. We envision that NanoVelcro CTC assays will lead the way for powerful and cost-efficient diagnostic platforms for researchers to better understand underlying disease mechanisms and for physicians to monitor real-time disease progression.
    Accounts of Chemical Research 08/2014; DOI:10.1021/ar5001617 · 24.35 Impact Factor
Show more